Skip to main content
SpringerLink
Log in

Treatment burden in multiple myeloma according to comorbidity in real life

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Rajkumar SV, Kumar S (2020) Multiple myeloma current treatment algorithms. Blood Cancer J 10:94. https://doi.org/10.1038/s41408-020-00359-2

    Article  PubMed  PubMed Central  Google Scholar 

  2. Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC (2018) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J 8:109. https://doi.org/10.1038/s41408-018-0141-0

    Article  PubMed  PubMed Central  Google Scholar 

  3. Costa LJ, Hari PN, Kumar SK (2016) Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma 57:2827–2832. https://doi.org/10.3109/10428194.2016.1170828

    Article  PubMed  Google Scholar 

  4. Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J (2019) A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 34:224–233. https://doi.org/10.1038/s41375-019-0539-0

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175:252–264. https://doi.org/10.1111/bjh.14213

    Article  PubMed  PubMed Central  Google Scholar 

  6. Knauf W, Aldaoud A, Hutzschenreuter U et al (2018) Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German Tumour Registry Lymphatic Neoplasms. Ann Hematol 97:2437–2445. https://doi.org/10.1007/s00277-018-3449-8

    Article  PubMed  PubMed Central  Google Scholar 

  7. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, Rifai AH, Mulsant B, Reynolds CF III (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41:237–248

    Article  CAS  Google Scholar 

  8. Rajkumar SV, Richardson P, San Miguel JF (2015) Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood 126:921–922

    Article  CAS  Google Scholar 

  9. Rajkumar SV, Harousseau J-L, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J, on behalf of the International Myeloma Workshop Consensus Panel 1 (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:4691–4695. https://doi.org/10.1182/blood-2010-10-299487

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Klausen TW, Gregersen H, Abildgaard N, Andersen NF, Frølund UC, Gimsing P, Helleberg C, Vangsted AJ (2019) The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials. Leukemia 33:546–549. https://doi.org/10.1038/s41375-018-0272-0

    Article  PubMed  Google Scholar 

  11. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M (2014) Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101–1110. https://doi.org/10.1056/NEJMoa1313984

    Article  CAS  PubMed  Google Scholar 

  12. Fischer K, Al-Sawaf O, Bahlo J et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 380:2225–2236. https://doi.org/10.1056/NEJMoa1815281

    Article  CAS  PubMed  Google Scholar 

  13. Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC (2018) Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 379:2517–2528. https://doi.org/10.1056/NEJMoa1812836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Abel GA, Klepin HD (2018) Frailty and the management of hematologic malignancies. Blood 131:515–524. https://doi.org/10.1182/blood-2017-09-746420

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Enrique Sala Ledesma for translation assistant.

Author information

Authors and Affiliations

  1. Department of hematology, Osakidetza Basque Health Service, Araba University Hospital, C/ José Achótegui s/n, 01009, Vitoria-Gasteiz, Spain

    Ernesto Pérez Persona, Laida Cuevas Palomares, Diego Robles de Castro, Carlos Miguel de Sánchez, Miren Gabilondo Jalón, Carlos Pisón Herrero, Ariane Unamunzaga Cilaurren, Ana Vega González de Viñaspre & Jose María Guinea de Castro

  2. Department of hematology, Osakidetza Basque Health Service. Hospital Universitario de Cruces, Barakaldo, Spain

    Itziar Oiartzabal Ormategui

  3. Department of hematology, Complejo hospitalario Universitario de Vigo, Vigo, Spain

    Ana Santamaría López

Authors
  1. Ernesto Pérez Persona
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Itziar Oiartzabal Ormategui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laida Cuevas Palomares
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Santamaría López
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diego Robles de Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlos Miguel de Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miren Gabilondo Jalón
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carlos Pisón Herrero
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ariane Unamunzaga Cilaurren
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ana Vega González de Viñaspre
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jose María Guinea de Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EPP and IOO conceived and designed the work, and with JGC drafted the manuscript and approved the final version. LCP, ASL, DRC, CMS, MGJ, CPH, AUC, AVG: review patient’s charts, collect the data, and approved the final version.

Corresponding author

Correspondence to Ernesto Pérez Persona.

Ethics declarations

Ethics approval

The study was approved by the hospital ethic committee.

Consent to participate

Not applicable.

Conflict of interest

EPP participated in advisory boards from Celgene, Amgen, and Jansseng.

IOO participated in advisory board from Celgene.

GMA participated in advisory board from Leo Pharma.

LCP, ASL, DRC, CMS, MGJ, CPH, IPS, AUC, and AVG declare no conflict of interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pérez Persona, E., Oiartzabal Ormategui, I., Cuevas Palomares, L. et al. Treatment burden in multiple myeloma according to comorbidity in real life. Ann Hematol 101, 437–440 (2022). https://doi.org/10.1007/s00277-021-04462-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04462-7

Search

Navigation